BridgeMD
New treatment option for Endometrioma
Official title Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis
ClinicalTrials.gov ID: NCT06955221
What this study is testing
- What it's testing
- The goal of this clinical trial is to evaluate whether ultrasound-guided alcohol sclerotherapy can improve pelvic pain and quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas, compared to expectant management. The main questions it aims to answer are: 1.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 45, women only
You may be able to join if
- Female sex
- Age ≥18 and ≤45 years
- Ultrasound suspicion of unilocular endometrioma or with a thin septum less than 3 mm
- Size between 30-100 mm, persistent for at least 3-6 months since diagnosis
- Ca125 marker \<300 UI/mL and HE4 \< 70 pM
You likely can't join if
- Age \ 45 years
- History of ovarian or uterine cancer
- Endometrioma size \ 100 mm
- Indication for surgical treatment of the endometrioma due to suspected severe extra-ovarian endometriosis or any other cause
- Ultrasound suspicion of dermoid cysts, anechoic cysts, or cysts with high risk of malignancy
- Ca125 \>300 UI/mL
See the full eligibility criteria
- Female sex
- Age ≥18 and ≤45 years
- Ultrasound suspicion of unilocular endometrioma or with a thin septum less than 3 mm
- Size between 30-100 mm, persistent for at least 3-6 months since diagnosis
- Ca125 marker \<300 UI/mL and HE4 \< 70 pM
- Signed informed consent
- Age \ 45 years
- History of ovarian or uterine cancer
- Endometrioma size \ 100 mm
- Indication for surgical treatment of the endometrioma due to suspected severe extra-ovarian endometriosis or any other cause
- Ultrasound suspicion of dermoid cysts, anechoic cysts, or cysts with high risk of malignancy
- Ca125 \>300 UI/mL
- HE4 \>70 pM
- Pregnant women
- Patients who do not wish to participate in the study or who are mentally incapacitated
The study team makes the final eligibility decision.
Where it's taking place
- Palma de Mallorca, Balearic Islands, Spain
- Badalona, Barcelona, Spain
- Granollers, Barcelona, Spain
- Igualada, Barcelona, Spain
- L'Hospitalet de Llobregat, Barcelona, Spain
- Martorell, Barcelona, Spain
- Sabadell, Barcelona, Spain
- Sant Boi de Llobregat, Barcelona, Spain
- Sant Cugat del Vallès, Barcelona, Spain
- Viladecans, Barcelona, Spain
- Arrecife, Canary Islands, Spain
- Logroño, La Rioja, Spain
- San Javier, Murcia, Spain
- Gijón, Principality of Asturias, Spain
- San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
- Reus, Tarragona, Spain
- Barcelona, Spain
- Burgos, Spain
- Granada, Spain
- Jaén, Spain
+ 5 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 45 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Palma de Mallorca, Balearic Islands, Spain; Badalona, Barcelona, Spain; Granollers, Barcelona, Spain; Igualada, Barcelona, Spain; L'Hospitalet de Llobregat, Barcelona, Spain; Martorell, Barcelona, Spain and 19 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.